CVRx, Inc.

MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations featuring Barostim at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026.

Landry Brings Two Decades of Medtech and Public Company Finance Experience Landry Brings Two Decades of Medtech and Public Company Finance Experience

CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.

MINNEAPOLIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today issued the following statement in response to the public letter to CVRx's Board of Directors from Jorey Chernett at Pointillist Family Office, dated August 24, 2026: The Board of Directors and leadership team are committed to acting in the best interests of all CVRx shareholders and regularly evaluate a full range of options to maximize value for all shareholders. The Board values all shareholder input and appreciates the open dialogue the Company has maintained with Mr.